Ipatasertib

Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models.


Cat. No.: EX-A2077	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
250mg	585	In-stock
500mg	785	In-stock
1g	1185	In-stock
5g	3860	In-stock
10g	6350	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	GDC-0068
Synonyms 2	RG7440
CAS No.	1001264-89-6
Purity	>98%
Formula	C24H32ClN5O2
Mol Weight	457.996
Appearance	solid powder
Solubility	Soluble in DMSO/water
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Sun L, et al. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. Cell Death Dis. 2018 Sep 5;9(9):911. [2]. Blake JF, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012 Sep 27;55(18):8110-27.
CoA	CoA of Ipatasertib

Smiles:	CC(C)NC[C@@H](C(=O)N1CCN(CC1)C1=C2[C@H](C)C[C@@H](O)C2=NC=N1)C1=CC=C(Cl)C=C1


		Search